Nilanka Perera

Dr. Nilanka Perera


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2017 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
NPNilanka Perera
Nilanka Perera
JMJoanna L. Miller
Joanna L. Miller
NZNicole Zitzmann
Nicole Zitzmann

14 November 2024 in Clinical Nutrition
Verified
Journal Article
Closed access
XZXiao-Dong Zhou
Xiao-Dong Zhou
QCQin-Fen Chen
Qin-Fen Chen
Giovanni TargherGiovanni Targher
Giovanni Targher
CBChris Byrne
Chris Byrne
CMChristos S. Mantzoros
Christos S. Mantzoros
MZMing-Hua Zheng
Ming-Hua Zheng

12 February 2016 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
NPNilanka Perera
Nilanka Perera
JIJegarajah Indrakumar
Jegarajah Indrakumar
WAWaruni Vijitha Abeysinghe
Waruni Vijitha Abeysinghe
VFVihangi Fernando
Vihangi Fernando
WSW. M. C. K. Samaraweera
W. M. C. K. Samaraweera
JLJayamal Sanjaya Lawrence
Jayamal Sanjaya Lawrence
Non alcoholic fatty liver disease is an independent risk factor for coronary artery disease. But its effect on acute coronary syndrome is not clear. We performed this study to identify the prevalence of NAFLD in patients with ACS admitted to a tertiary care center in Sri Lanka. We also described the association of NAFLD with the severity of ACS predicted by the GRACE score. We performed a descriptive study including all consecutive patients with non-fatal ACS admitted to Colombo South Teaching Hospital from 01/02/2014 to 30/04/2014. Patients with excessive alcohol consumption, established cirrhosis and patients with identified risk factors for liver disease were excluded from the study. All patients underwent ultrasound scan of liver. There were 120 participants, 75 (62.5 %) males and 45 (37.5 %) females with acute coronary syndrome. Average age was 61.28 ± 11.83 years. NAFLD was seen in 56 (46.7 %) patients with ACS. Patients with NAFLD had a higher GRACE score than patients without NAFLD (120.2 ± 26.9 Vs 92.3 ± 24.2, p < 0.001). Increased age and presence of NAFLD conferred a higher mortality risk from ACS as predicted by GRACE score. Patients with NAFLD had a higher predicted mortality during in-ward stay (adjusted OR 31.3, CI 2.2–439.8, p = 0.011) and at 6 months after discharge (adjusted OR 15.59, CI 1.6–130.6, p = 0.011). Patients with NAFLD have a higher predicted mortality from acute coronary syndrome and thus require aggressive treatment of CAD. It is important to consider this novel risk factor when risk stratifying patients with ACS.

20 March 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMPmw Madanayake
Pmw Madanayake
AJAeu Jayawardena
Aeu Jayawardena
SWS L Wijekoon
S L Wijekoon
NPNilanka Perera
Nilanka Perera
JWJkp Wanigasuriya
Jkp Wanigasuriya
Background: Dengue fever prevalence is rising globally and it causes significant morbidity and mortality. Fluid extravasation during the critical phase of dengue haemorrhagic fever (DHF) leads to shock, multi-organ failure and death if not resuscitated appropriately with fluids. The mainstay of management is judicious fluid replacement using a guideline based, calculated fluid quota of maintenance (M) fluid plus 5% deficit (M + 5% deficit) to prevent organ hypoperfusion.Methods: We conducted an observational follow-up study in Sri Lanka from January–July 2017 to identify the fluid requirements of DHF patients and to identify whether features of fluid overload are present in patients who exceeded the fluid quota. Patients who developed DHF following admission to the place of study, were recruited and the amount of fluid received during the critical phase was documented.Results: A total of 115 DHF patients with a mean age of 30.3 (SD 12.2) years were recruited to the study. There were 65 (56.5%) males and the mean fluid requirement was 5279.7 ml (SD 735) over the 48 h. Majority of the study participants (n = 80, 69.6%) received fluid in excess of the recommended maintenance + 5% deficit and this group had higher body mass index (22.75 vs 20.76, p0.03) and a lower white cell count at the onset of the critical phase (3.22 × 103vs 4.78 × 103,p < 0.001). The highest fluid requirement was seen within the first 12 and 24 h of the critical phase in patients requiring fluid M + 5%–7.5% deficit and ≥ M + 7.5% deficit respectively. Patients exceeding M + 5% deficit had narrow pulse pressure and hypotension compared to the rest. DHF grades III and IV were seen exclusively in patients exceeding the fluid quota indicating higher amount of fluid was given for resuscitation. Fluid overload was detected in 14 (12.1%) patients and diuretic therapy was required in 6 (5.2%) patients.Conclusions: The majority of patients received fluid in excess of the recommended quota and this group represents patients with narrow pulse pressure and hypotension. Although, fluid overload was infrequent in the study population, clinicians should be cautious when administering fluid in excess of M + 7.5% deficit.

3 January 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CWChutian Wu
Chutian Wu
Giovanni TargherGiovanni Targher
Giovanni Targher
CBChris Byrne
Chris Byrne
YMYilei Mao
Yilei Mao
TCTan To Cheung
Tan To Cheung
MZMing-Hua Zheng
Ming-Hua Zheng
INTRODUCTION: The global burden of metabolic diseases is increasing, but estimates of their impact on primary liver cancer are uncertain. We aimed to assess the global burden of primary liver cancer attributable to metabolic risk factors, including high body mass index (BMI) and high fasting plasma glucose (FPG) levels, between 1990 and 2021. METHODS: The total number and age-standardized rates of deaths and disability-adjusted life years (DALYs) from primary liver cancer attributable to each metabolic risk factor were extracted from the Global Burden of Disease Study 1990–2021. The metabolic burden trends of liver cancer across regions and countries by sociodemographic index (SDI) and sex were estimated. The annual percentage changes in age-standardized DALYs rate were also calculated. RESULTS: Globally, in 2021, primary liver cancer attributable to high BMI and/or high FPG was estimated to have caused 59,970 deaths (95% uncertainty interval [UI] 20,567–104,103) and 1,540,437 DALYs (95% UI 540,922–2,677,135). The age-standardized rates of death and DALYs were 0.70 (95% UI 0.24–1.21) and 17.64 (95% UI 6.19–30.65) per 100,000 person-years. A consistent global rise in liver cancer attributable to metabolic risks was observed from 1990 to 2021, with high BMI identified as the major contributing risk factor. The highest burden of deaths and DALYs of liver cancer consistently occurred in high SDI countries, while the fastest growth trends were observed in low-middle SDI countries. The burdens of high levels of BMI and FPG were higher in men than in women. DISCUSSION: Primary liver cancer attributable to high BMI and/or high FPG imposes an increasingly substantial clinical burden on global public health, particularly in high SDI countries. Rapid growth trends are also found in middle SDI countries.

25 February 2022 in Antiviral Research
Verified
Journal Article
Open access
NPNilanka Perera
Nilanka Perera
JBJuliane Brun
Juliane Brun
DADominic S. Alonzi
Dominic S. Alonzi
BTBeatrice E. Tyrrell
Beatrice E. Tyrrell
JMJoanna L. Miller
Joanna L. Miller
NZNicole Zitzmann
Nicole Zitzmann
Dendritic cells (DCs) are important targets for dengue virus (DENV) infection and play a significant role in the early immune response. Antiviral effects of iminosugars against DENV in primary cells have been demonstrated previously in monocyte-derived macrophages (MDMΦs). Given the important role played by DCs in innate immune defense against DENV, the antiviral effects of three deoxynojirimycin (DNJ) derivatives (NN-DNJ, EOO-DNJ and 2THO-DNJ) and a deoxygalactonojirimycin (DGJ) negative control were evaluated in DENV-infected primary human monocyte-derived immature DCs (imDCs). DNJ- but not DGJ-derivatives elicited antiviral activity in DENV-infected imDCs, similar to that observed in MDMΦs. The DNJ-derivatives inhibited DENV secretion in a dose-dependent manner. Endoplasmic reticulum (ER) α-glucosidase I inhibition by DNJ-derived iminosugars, at concentrations of 3.16 μM, correlated with a reduction in the specific infectivity of virions that were still secreted, as well as a reduction in DENV-induced tumour necrosis factor alpha secretion. This suggests iminosugar-mediated ER α-glucosidase I inhibition may give rise to further benefits during DENV infection, beyond the reduction in viral secretion associated with ER α-glucosidase II inhibition.